Clinical and pharmacological group: & nbsp

Alkylating agents

Antineoplastic agents

Included in the formulation
  • Aranosa
    lyophilizate in / in 
    Company DEKO, LLC     Russia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    ONLS

    АТХ:

    L.01.X.X   Other antineoplastic agents

    Pharmacodynamics:

    In the nuclei of tumor cells produces an alkylating effect on molecules deoxyribonucleic acid, disconnecting the nucleotide chains. As a result, synthesis deoxyribonucleic acids in tumor cells stops.

    Pharmacokinetics:Not studied.
    Indications:

    It is used to treat skin melanoma.

    II.C43-C44.C43.9   Malignant melanoma of skin, unspecified

    Contraindications:

    Leukopenia - less than 3 thousand in μl.

    Thrombocytopenia is less than 120 thousand in μl.

    Exacerbation of peptic ulcer of the stomach and duodenum.

    Severe renal and hepatic insufficiency.

    Individual intolerance.

    Carefully:

    In severe anemia - control the number of blood elements.

    Pregnancy and lactation:

    Recommendations for Food and Drug Administration (US Food and Drug Administration) - not defined. In pregnant women, the drug is not used. Data on ingestion in breast milk are not available. It is recommended to stop breastfeeding during treatment.

    Dosing and Administration:

    The contents of the vial are diluted with 5% dextrose solution in an amount of 20 ml. Enter intravenously struyno 0.5-0.8 g / m2 the entire surface of the patient's body every other day or every day. The course of treatment - 3 injections.

    The repeated course is carried out according to the indications no earlier than 4 weeks later.

    The highest daily dose: 1.5 g.

    The highest single dose: 1.5 g.

    The course dose: 3-4.5 g.

    Side effects:

    The system of hematopoiesis: anemia, thrombocytopenia, leukopenia - can develop 1-3 weeks after the course of treatment.

    Immunodepression.

    Allergic reactions.

    Overdose:

    Aplastic anemia, dyspeptic disorders.

    Treatment is symptomatic.

    Interaction:

    Strengthens the effect of other antitumor agents, without affecting toxicity.

    Special instructions:

    Treatment is carried out under the control of a general blood test - before treatment and daily during the course of therapy.

    Myelosuppression caused by taking the drug, leads to the emergence of bacterial infections, reduces the regenerative processes of wound healing, promotes bleeding gums. It is recommended to sanitize the oral cavity before starting chemotherapy.

    Instructions
    Up